Journal of Clinical Medicine (Jun 2021)
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
- Ahmad Albshesh,
- Joshua Taylor,
- Edoardo V. Savarino,
- Marie Truyens,
- Alessandro Armuzzi,
- Davide G. Ribaldone,
- Ariella Bar-Gil Shitrit,
- Morine Fibelman,
- Pauliina Molander,
- Claire Liefferinckx,
- Stephane Nancey,
- Mohamed Korani,
- Mariann Rutka,
- Manuel Barreiro-de Acosta,
- Viktor Domislovic,
- Gerard Suris,
- Carl Eriksson,
- Catarina Alves,
- Afroditi Mpitouli,
- Caroline di Jiang,
- Katja Tepeš,
- Marina Coletta,
- Kalliopi Foteinogiannopoulou,
- Javier P. Gisbert,
- Hadar Amir-Barak,
- Mohamed Attauabi,
- Jakob Seidelin,
- Waqqas Afif,
- Carla Marinelli,
- Triana Lobaton,
- Daniela Pugliese,
- Nitsan Maharshak,
- Anneline Cremer,
- Jimmy K. Limdi,
- Tamás Molnár,
- Borja Otero-Alvarin,
- Zeljko Krznaric,
- Fernando Magro,
- Konstantinos Karmiris,
- Tim Raine,
- David Drobne,
- Ioannis Koutroubakis,
- Maria Chaparro,
- Henit Yanai,
- Johan Burisch,
- Uri Kopylov
Affiliations
- Ahmad Albshesh
- Sheba Medical Center, Department of Gastroenterology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 52621, Israel
- Joshua Taylor
- Department of Gastroenterology, Montreal General Hospital, Montreal, QC 1650, Canada
- Edoardo V. Savarino
- Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy
- Marie Truyens
- IBD Unit, Department of Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium
- Alessandro Armuzzi
- IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
- Davide G. Ribaldone
- Division of Gastroenterology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
- Ariella Bar-Gil Shitrit
- Shaare Zedek Medical Center, Faculty of Medicine, Digestive Diseases Institute, Hebrew University of Jerusalem, Jerusalem 9372212, Israel
- Morine Fibelman
- Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6423906, Israel
- Pauliina Molander
- Abdominal Center, Department of Gastroenterology, Helsinki University Hospital, 00101 Helsinki, Finland
- Claire Liefferinckx
- Department of Gastroenterology, Erasme University Hopital, 1070 Brussels, Belgium
- Stephane Nancey
- Department of Gastroenterology, Hospices Civils de Lyon, University Claude Bernard Lyon, 69495 Lyon, France
- Mohamed Korani
- Division of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester M8 6RB, UK
- Mariann Rutka
- First Department of Medicine, University of Szeged, H-6720 Szeged, Hungary
- Manuel Barreiro-de Acosta
- IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago, Spain
- Viktor Domislovic
- Department of Gastroenterology, Hepatology, and Nutrition, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
- Gerard Suris
- Digestive System Service, Bellvitge University Hospital, Catalan Institute of Health, 08907 Barcelona, Spain
- Carl Eriksson
- Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, SE-70182 Örebro, Sweden
- Catarina Alves
- Department of Gastroenterology, Centro Hospitalar São João, 4200319 Porto, Portugal
- Afroditi Mpitouli
- Department of Gastroenterology, Venizeleion General Hospital, Heraklion, 71409 Crete, Greece
- Caroline di Jiang
- Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge CB2 0QQ, UK
- Katja Tepeš
- University Medical Centre Ljubljana, Department of Gastroenterology, Medical Faculty, University of Ljubljana, 1231 Ljubljana, Slovenia
- Marina Coletta
- Department of Hepatology and Clinical Gastroenterology, ASST Santi Paolo e Carlo-Ospedale San Polo Universitario Milano Mariabeatrice, 20142 Milan, Italy
- Kalliopi Foteinogiannopoulou
- Department of Gastroenterology, University Hospital of Heraklion, 71500 Crete, Greece
- Javier P. Gisbert
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, 28001 Madrid, Spain
- Hadar Amir-Barak
- IBD Center, Division of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel and the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 49100, Israel
- Mohamed Attauabi
- Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen, 2650 Copenhagen, Denmark
- Jakob Seidelin
- Department of Gastroenterology, Herlev University Hospital, 3400 Copenhagen, Denmark
- Waqqas Afif
- Department of Gastroenterology, Montreal General Hospital, Montreal, QC 1650, Canada
- Carla Marinelli
- Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, 35128 Padua, Italy
- Triana Lobaton
- IBD Unit, Department of Gastroenterology, Ghent University Hospital, 9000 Ghent, Belgium
- Daniela Pugliese
- IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
- Nitsan Maharshak
- Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6423906, Israel
- Anneline Cremer
- Department of Gastroenterology, Erasme University Hopital, 1070 Brussels, Belgium
- Jimmy K. Limdi
- Division of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester M8 6RB, UK
- Tamás Molnár
- First Department of Medicine, University of Szeged, H-6720 Szeged, Hungary
- Borja Otero-Alvarin
- IBD Unit, Gastroenterology Department, University Hospital of Santiago de Compostela, 15706 Santiago, Spain
- Zeljko Krznaric
- Department of Gastroenterology, Hepatology, and Nutrition, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
- Fernando Magro
- Department of Gastroenterology, Centro Hospitalar São João, 4200319 Porto, Portugal
- Konstantinos Karmiris
- Department of Gastroenterology, Venizeleion General Hospital, Heraklion, 71409 Crete, Greece
- Tim Raine
- Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge CB2 0QQ, UK
- David Drobne
- University Medical Centre Ljubljana, Department of Gastroenterology, Medical Faculty, University of Ljubljana, 1231 Ljubljana, Slovenia
- Ioannis Koutroubakis
- Department of Gastroenterology, University Hospital of Heraklion, 71500 Crete, Greece
- Maria Chaparro
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid, 28001 Madrid, Spain
- Henit Yanai
- IBD Center, Division of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel and the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 49100, Israel
- Johan Burisch
- Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen, 2650 Copenhagen, Denmark
- Uri Kopylov
- Sheba Medical Center, Department of Gastroenterology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv 52621, Israel
- DOI
- https://doi.org/10.3390/jcm10132914
- Journal volume & issue
-
Vol. 10,
no. 13
p. 2914
Abstract
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
Keywords